$NNOX

Meltzer Erez purchased $33K of NNOX (indirect holdings)

Meltzer Erez (Chief Executive Officer) purchased 36,000 indirectly-held shares of Nano-X Imaging Ltd. (NNOX) at $0.93 on 2026-07-27.

Original reporting
SEC EDGAR · Meltzer Erez
Published Jul 28, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NNOX
Bullish
medium confidence
Mentioned
$NNOX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NNOXBullishLow
01

Why it matters

An insider open-market purchase can slightly improve sentiment, but the filing does not introduce new company-specific fundamentals (no guidance, trial results, or deal terms).

02

Market read

Traders may note the insider buy as a minor sentiment input, but it is unlikely to change valuation without additional catalysts.

03

What to watch

No follow-on guidance, trial, contract, or financing details are provided, so traders should avoid extrapolating this buy into fundamental upside.

Relevance 4/10Novelty 3/10Timing: just filed on 2026-07-28 after-hours/filing window

Background

This is an SEC Form 4 insider transaction disclosure for Nano-X Imaging Ltd.

Company-level read

Ticker impact

$NNOXBullishMedium confidence
Context

Nano-X Imaging CEO Meltzer Erez filed a Form 4 open-market purchase of 36,000 shares at $0.93 on 2026-07-27.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, but the transaction size ($33.5k) is modest and the article provides no new operational or financial developments.

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase is indirect and small, and without a 10b5-1 plan it may reflect liquidity or personal timing rather than a strong forward view.

Key entities

  • Nano-X Imaging Ltd.

    Subject of the Form 4 insider transaction disclosure.

  • Meltzer Erez

    CEO and director who purchased shares via an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NNOXMed

Nano X Imaging Ltd (NNOX) (Q2 2026) Earnings Call Highlights: Re

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

$NNOXHigh

Nano-X Imaging Ltd. (NNOX): Financial results for Q2 2026

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

$NNOXMed

NANO-X IMAGING LTD: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.